Exclusive Summary

• Targeting a multi-billion dollar market driven by a massive global patient base, with GERD prevalence reaching 8%-33% globally and requiring long-term maintenance therapy.
• Recommended as a first-line acid suppressant by global guidelines, pantoprazole offers a superior safety profile with fewer drug-drug interactions (e.g., with clopidogrel) compared to omeprazole.
• The original patent has long expired, resulting in zero market education costs, making it highly suitable for rapid market penetration and capturing existing shares via the Distribution model.
• The enteric-coated formulation demonstrates strong manufacturing capabilities, while the 20mg and 40mg specifications perfectly cover both acute treatment and long-term maintenance clinical needs.
• Backed by China's API+FDF integrated supply chain, the product offers significant cost advantages and supply stability, ensuring high profit margins for overseas distributors in tenders and retail channels.